低危甲状腺微小乳头状癌热消融治疗的现状与思考  

Current status and reflections on thermal ablation therapy for papillary thyroid microcarcinoma

作　　者：张俊平 刘莹[1] 徐积兄[1] Zhang Junping;Liu Ying;Xu Jixiong(Department of Endocrinology and Metabolism,the First Affiliated Hospital,Jiangxi Medical College,Nanchang University,Jiangxi Clinical Research Center for Endocrine and Metabolic Disease,Jiangxi Branch of National Clinical Research Center for Metabolic Disease,Nanchang 330006,China)

机构地区：[1]南昌大学江西医学院第一附属医院内分泌代谢科,江西省内分泌代谢病临床医学研究中心,国家代谢性疾病临床医学研究中心江西分中心,南昌330006

出　　处：《国际内分泌代谢杂志》2025年第1期1-5,共5页International Journal of Endocrinology and Metabolism

基　　金：江西省科技创新基地建设-临床医学研究中心(20221ZDG02011);江西省科技创新基地计划-省临床医学研究中心(2020BCG74001);江西省自然科学基金(20224ACB206010)。

摘　　要：甲状腺微小乳头状癌(PTMC)是目前患病率较高的内分泌肿瘤之一。由于其进展和死亡风险较低,热消融已被用于治疗低危PTMC。越来越多的证据表明,热消融治疗低危PTMC在安全性和疗效方面具有良好表现。同时,随着研究证据的积累,热消融治疗PTMC的适应证也在不断拓宽。然而,热消融治疗也存在一定的局限性,仍需密切随访,以评估其长期疗效。未来,需要开展更多中心的前瞻性研究,以提供更高质量的循证医学证据,并推动相关的系统培训,以规范其临床实践。Papillary thyroid microcarcinoma(PTMC)is one of the most common endocrine tumors with a high incidence rate.Due to its low risk of progression and mortality,thermal ablation has been used to treat low-risk PTMC.Increasing evidence suggests that thermal ablation for low-risk PTMC demonstrates good performance in terms of safety and efficacy.Additionally,with the accumulation of research evidence,the indications for thermal ablation in treating PTMC are continuously expanding.In the future,more prospective studies in various centers are needed to provide higher-quality evidence in evidence-based medicine and to promote relevant systematic training to standardize its clinical practice.

关 键 词：甲状腺微小乳头状癌 热消融 射频消融 微波消融 

分 类 号：R73[医药卫生—肿瘤]